Q.P. Code :00984

[Time: Two Hours] **[Marks:35]**

Please check whether you have got the right question paper.

N.B: 1. All questions are compulsory.
2. Figures to right side Indicate full marks.

Q. 1 Answer the following. **07**

i. Write benefits offered by community pharmacist to the patients.
ii. Explain the role of drug analysis method for detecting non-compliance.
iii. Write examples of drugs causing hemolytic anemia as a allergic responses.
iv. How does impaired renal function contribute to drug interaction?
v. Enlist various reasons restricting administration of drug in first trimester of pregnancy.
vi. Comment on influence of sampling time for effective TDM.
vii. Define pharmacovigilance.

Q. 2 A. Answer **any one** of the following **04**

i. Define patient counselling. Explain with examples instructions for administering any two dosage forms.
ii. Discuss $3C^s$ of clinical pharmacy services

B. Answer the following **03**

i. Enlist reasons for non-compliance. Explain role of patient counseling and education to improve compliance.

Q. 3 A. Answer **any one** of the following **04**

i. How does dosage error leads to Adverse drug reactions. Explain role of cohort studies in detecting ADR.
ii. Describe role of pharmacist in reporting of Adverse drug reactions.

B. Answer the following **03**

i. Write need for therapeutic drug monitoring.

Q. 4 A. Answer **any one** of the following **04**

i. Write reasons for drug interactions. Explain pharmacodynamic interaction due to alteration of electrolyte level and due to MAO inhibitor.
ii. Explain in brief with examples. How self-medication of over the counter product (OTC) contributes to produce potential Drug- drug interactions.

B. Answer the following **03**

i. Define & explain in brief rational use of medication in pediatrics.

Q. 5 Answer **any one** of the following **04**

i. Write different types of clinical trials. Discuss in detail confirmatory clinical trials.
ii. Explain cross over design. Write the role and responsibility of institutional review board (IRB) while execution of clinical trials.

B. Answer the following **03**

i. Write a short note on lead optimization in drug development.
